Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study aims to assess whether phenotyping-guided intervention selection is superior to intervention selection without phenotyping guidance (i.e., routine clinician and patient judgment regarding treatment selection) for depression.
This study will classify patients seen in the Depression Clinic of the UCSF Department of Psychiatry and Behavioral Sciences into one of five phenotypes (subtypes), including: 1) Anhedonia, 2) Cognitive deficits, 3) Stress sensitivity, 4) Anxious distress, and 5) Grief.
After phenotyping, participants will be randomized to receive phenotype-specific intervention (PSI) or care as usual (CAU).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Anhedonia phenotype: PSI | Experimental |
| |
| Anhedonia phenotype: CAU | Active Comparator |
| |
| Cognitive deficits: PSI | Experimental |
| |
| Cognitive deficits: CAU | Active Comparator |
| |
| Stress sensitivity: PSI | Experimental |
| |
| Stress sensitivity: CAU | Active Comparator |
| |
| Anxious distress: PSI | Experimental |
| |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Pramipexole | Drug | CAU plan modified to include a trial of pramipexole. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Quick Inventory of Depressive Symptoms - Self-Report 16-Item (QIDS-SR-16) score | Within-phenotype and across-phenotype contrasts. | Up to 24 weeks after randomization. |
| Measure | Description | Time Frame |
|---|---|---|
| Snaith-Hamilton Pleasure Scale (SHAPS) score | For anhedonia phenotype only. | Up to 24 weeks after randomization. |
| Clinically Useful Depression Outcome Scale Anxious Distress Specifier Subscale (CUDOS-A) score |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Andrew D. Krystal, MD | University of California, San Francisco | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Nancy Friend Pritzker Psychiatry Building, University of California, San Francisco | San Francisco | California | 94107 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Anxious distress: CAU |
| Active Comparator |
|
| Grief: PSI | Experimental |
|
| Grief: CAU | Active Comparator |
|
| Methylphenidate |
| Drug |
CAU plan modified to include a trial of methylphenidate (or, if contraindicated: guanfacine). |
|
| Phenelzine | Drug | CAU plan modified to include a trial of phenelzine (or, if contraindicated: brexpiprazole). |
|
| Mindfulness-based Stress Sensitivity Therapy (MBSST) | Behavioral | CAU plan modified to include a trial of MBSST. MBSST is an individual psychotherapy delivered approximately weekly for 16 sessions. |
|
| Complicated Grief Treatment (CGT) | Behavioral | CAU plan modified to include a trial of CGT. |
|
| Care as usual (CAU) plan | Other | Unmodified CAU plan. |
|
For anxious distress phenotype only.
| Up to 24 weeks after randomization. |
| Generalized Anxiety Disorder 7-item (GAD-7) score | For anxious distress phenotype only. | Up to 24 weeks after randomization. |
| Inventory of Complicated Grief (ICG) score | For grief phenotype only. | Up to 24 weeks after randomization. |
| Perceived Deficits Questionnaire - Depression (PDQ-D) score | For cognitive deficits phenotype only. | Up to 24 weeks after randomization. |
| Patient Health Questionnaire - 8 (PHQ-8) score | Within-phenotype and across-phenotype contrasts. | Up to 24 weeks after randomization. |
| WHO Disability Assessment Schedule (WHODAS 2.0) | Within-phenotype and across-phenotype contrasts. | Up to 24 weeks after randomization. |
| Quick Inventory of Depressive Symptoms - Self-Report 16-Item (QIDS-SR-16) response | 50% reduction from baseline score. Within-phenotype and across-phenotype contrasts. | Up to 24 weeks after randomization. |
| Quick Inventory of Depressive Symptoms - Self-Report 16-Item (QIDS-SR-16) remission | Score < 6. Within-phenotype and across-phenotype contrasts. | Up to 24 weeks after randomization. |
| ID | Term |
|---|---|
| D003865 | Depressive Disorder, Major |
| D003863 | Depression |
| ID | Term |
|---|---|
| D003866 | Depressive Disorder |
| D019964 | Mood Disorders |
| D001523 | Mental Disorders |
| D001526 | Behavioral Symptoms |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077487 | Pramipexole |
| D008774 | Methylphenidate |
| D010624 | Phenelzine |
| ID | Term |
|---|---|
| D052160 | Benzothiazoles |
| D013844 | Thiazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010648 | Phenylacetates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
| D010880 | Piperidines |
| D006834 | Hydrazines |
Not provided
Not provided